Product Description
REVTx-99 is a nasal solution for the prevention and/or treatment of respiratory viral infection and chronic nasal congestion. (Sourced from: https://www.revbiosciences.com/phase1-2)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Revelation Biosciences
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Influenza, Human
Phase 1: COVID-19|Rhinitis, Allergic
Phase 0: Food Hypersensitivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12621001455853 |
ACTRN12621001455853 | P1 |
Completed |
Rhinitis, Allergic |
2022-05-12 |
2025-02-10 |
Patient Enrollment|Primary Completion Date|Start Date |
|
ACTRN12620001104943 |
ACTRN12620001104943 | P1 |
Completed |
COVID-19 |
2021-02-15 |
2024-08-29 |
Treatments |
|
2021-003463-97 |
2021-003463-97 | P2 |
Completed |
Influenza, Human |
2022-04-06 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/22/2024 |
News Article |
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 |
|
11/13/2023 |
News Article |
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 |
|
08/11/2023 |
News Article |
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 |
|
05/22/2023 |
News Article |
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress |